AbbVie Acquires Mavupharma to Advance STING-Targeted Cancer Immunotherapies

Recently, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that biopharmaceutical giant AbbVie has announced the acquisition of drug development company Mavupharma to advance the research, development, and production of anticancer drugs. No financial terms of the acquisition were disclosed.

It is reported that Mavupharma completed a $20 million Series A financing round in November 2017, led by Frazier Healthcare Partners and Alpine BioVentures.

Mavupharma, founded in 2016 and headquartered in Washington State, USA, is a biotechnology and pharmaceutical R&D company. The company is dedicated to exploring targeted therapeutic pathways for the stimulator of interferon genes (STING) protein, developing drugs that enhance the function of the human immune system to combat cancer and infectious diseases.

STING is widely present in mammals and serves as an important receptor protein located on the endoplasmic reticulum membrane. It detects microbial pathogens, including bacteria, viruses, and parasites, that invade host cells, and activates intracellular TANK-binding kinase 1 (TBK1) and interferon regulatory factors (IRFs), thereby inducing the production of type I interferons and pro-inflammatory cytokines to eliminate pathogenic microorganisms. STING is not only pivotal in innate immune responses but also participates in various physiological and pathological processes, such as tumor immunity, autoimmune inflammation, and autophagy. Therefore, investigating the function and underlying mechanisms of STING can enhance our understanding of these pathological processes and provide novel therapeutic targets for the clinical treatment of related diseases.

Mavupharma research has found that promoting the transduction of the STING signaling pathway can enhance the body's immune response to tumors. This mechanism holds broad application prospects in tumor treatment and could provide patients with more therapeutic options.

Mavupharma's lead clinical candidate, MAVU-104, is an oral small-molecule enzyme activity inhibitor that modulates the STING expression pathway. MAVU-104 significantly inhibits the activity of the phosphodiesterase ENPP1, thereby promoting STING signaling transduction.

AbbVie, established in 2013 and headquartered in Chicago, USA, is a global biopharmaceutical company focused on drug research and development. The company’s mission is to leverage its expertise to develop advanced therapies for rare and chronic diseases in the fields of immunology, oncology, virology, and neuroscience.

AbbVie employs 30,000 people and operates in more than 75 countries worldwide. The company boasts experienced research teams, pharmaceutical experts, and regulatory professionals dedicated to studying complex diseases and providing new therapies for public health challenges. AbbVie leverages drug development technologies to advance medical progress, making a positive impact on patients, society, and the industry.

Dr. Steve Davidsen, Vice President of AbbVie, stated, “AbbVie aims to establish an effective pipeline for innovative cancer therapies to advance the field of oncology. Mavupharma’s platform will support AbbVie in developing anticancer drugs.”

Dr. Michael Gallatin, Co-Founder of Mavupharma, stated, “AbbVie holds a leadership position in the field of oncology, and their advanced technology will help Mavupharma explore new avenues for STING-targeted therapies and advance the clinical trials of MAVU-104. We are delighted to co-develop with AbbVie.”

(Compiled by Xu Xiaoxue)